Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 4.250 +0.100 (+2.41%) Streaming Delayed Price Updated: 3:16 PM EDT, May 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,637,276 Open 4.180 Bid (Size) 4.250 (4) Ask (Size) 4.260 (42) Prev. Close 4.150 Today's Range 4.080 - 4.390 52wk Range 1.630 - 8.830 Shares Outstanding 98,384,456 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates May 09, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Performance YTD +15.18% +15.18% 1 Month -24.65% -24.65% 3 Month -38.05% -38.05% 6 Month +113.57% +113.57% 1 Year -20.26% -20.26% More News Read More Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program May 09, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Forecasting The Future: 8 Analyst Projections For Fate Therapeutics May 06, 2024 Via Benzinga Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates May 06, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Where Fate Therapeutics Stands With Analysts April 11, 2024 Via Benzinga Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting May 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting April 22, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Evaluating Fate Therapeutics: Insights From 5 Financial Analysts March 19, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics February 27, 2024 Via Benzinga Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement March 19, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) March 05, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Recap: Fate Therapeutics Q4 Earnings February 26, 2024 Via Benzinga Fate Therapeutics to Present at Upcoming March Investor Conferences March 01, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday February 27, 2024 Via Benzinga Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates February 26, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For February 26, 2024 February 26, 2024 Via Benzinga A Preview Of Fate Therapeutics's Earnings February 23, 2024 Via Benzinga Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock January 29, 2024 Via InvestorPlace Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors January 08, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
